The duration of protection after vaccination with reduced antigen content diphtheria, tetanus
and acellular pertussis vaccines (Tdap) is not known. Long-term post-vaccination …

Reduced-antigen-content diphtheria–tetanus–acellular-pertussis (dTpa) vaccines are
predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™ …

There is increasing interest in prevention of pertussis in adults by vaccination, but little is
known about the duration of the antibody response to pertussis, diphtheria or tetanus in …

Background The tetanus, diphtheria and acellular pertussis vaccine (Tdap) was
recommended by the Advisory Committee on Immunization Practices (ACIP) for US adults in …

Introduction: Older children and adults, susceptible to pertussis because of waning
immunity, may serve as a reservoir of infection, leading to severe disease among young …

High rates of pertussis disease in adolescents suggest that additional boosting against
pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine …

BACKGROUND: Pre-licensure clinical trials for two US licensed tetanus toxoid, reduced
diphtheria toxoid and acellular pertussis (Tdap) vaccines did not reveal any major safety …

Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

Background Multivalent vaccines containing whole-cell pertussis (wP) antigens combined
with established diphtheria (D), tetanus (T), hepatitis B (HB), Haemophilus influenzae type b …

Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated
poliomyelitis and Haemophilus influenzae type b vaccine (DTaP-HBV-IPV/Hib) can further …